Multivariable analysis of PFS
| Covariate . | HR (95% CI) . | P value . |
|---|---|---|
| Time to first treatment | ||
| 15-60 d | Referent | |
| 0-14 d | 1.50 (1.20-1.87) | <.001 |
| Sex | ||
| Female | Referent | |
| Male | 1.39 (1.08-1.80) | .01 |
| Ann Arbor stage | ||
| 1-3 | Referent | |
| 4 | 0.90 (0.58-1.39) | .63 |
| BM involvement | ||
| No | Referent | |
| Yes | 1.40 (0.92-2.14) | .12 |
| B symptoms | ||
| No | Referent | |
| Yes | 1.20 (0.95-1.51) | .12 |
| MIPI | ||
| <5.7 | Referent | |
| ≥5.7 <6.2 | 1.23 (0.95-1.58) | .12 |
| ≥6.2 | 1.65 (1.27-2.15) | <.001 |
| Intensive induction therapy | ||
| No | Referent | |
| Yes | 0.69 (0.56-0.86) | .001 |
| Covariate . | HR (95% CI) . | P value . |
|---|---|---|
| Time to first treatment | ||
| 15-60 d | Referent | |
| 0-14 d | 1.50 (1.20-1.87) | <.001 |
| Sex | ||
| Female | Referent | |
| Male | 1.39 (1.08-1.80) | .01 |
| Ann Arbor stage | ||
| 1-3 | Referent | |
| 4 | 0.90 (0.58-1.39) | .63 |
| BM involvement | ||
| No | Referent | |
| Yes | 1.40 (0.92-2.14) | .12 |
| B symptoms | ||
| No | Referent | |
| Yes | 1.20 (0.95-1.51) | .12 |
| MIPI | ||
| <5.7 | Referent | |
| ≥5.7 <6.2 | 1.23 (0.95-1.58) | .12 |
| ≥6.2 | 1.65 (1.27-2.15) | <.001 |
| Intensive induction therapy | ||
| No | Referent | |
| Yes | 0.69 (0.56-0.86) | .001 |
Boldface value signifies statistically significant value.